Hosted on MSN14m
Leerink Partners Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...
Investor's Business Daily on MSN50m
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...